Irinotecan-hyaluronic acid complex - Monash University/Alchemia
Alternative Names: HA-irinotecan; Hyaluronan irinotecan complex; Hyaluronic acid irinotecan complex; HyCAMP; Irinotecan hyaluronan complexLatest Information Update: 01 Aug 2019
At a glance
- Originator Monash University
- Developer Alchemia
- Class Alkaloids; Antineoplastics; Camptothecins
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Small cell lung cancer
- Suspended Colorectal cancer
Most Recent Events
- 01 Aug 2019 Phase II development is ongoing in Australia (ACTRN12611000520932)
- 01 May 2015 Irinotecan-hyaluronic acid complex is still in phase II development for Small cell lung cancer in Australia
- 01 May 2015 Alchemia suspends a phase II trial in Colorectal cancer in Australia (NCT02216487)